Coronavirus: How does misinformation spread, and how can we stop it? – The Jerusalem Post
Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL – OncLive
For those who wish to combat COVID-related misinformation - such as the belief that vaccines contain microchips, or that the coronavirus vaccine causes infertility - it oftentimes feels like an uphill battle. Oftentimes, the issue emerges surrounding unproven treatments for coronavirus. In the peer-reviewed study, the researchers explain that despite no evidence backing such treatment, clinics have begun to pop up and offer stem cell therapies that "promise to prevent COVID-19 by strengthening the immune system or improving overall health," according to the University at Buffalo
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer – Business Wire
Brad S. Kahl, MD, discusses the potential utility of frontline CAR T-cell therapy in mantle cell lymphoma. Brad S
Harvard’s R&D alliance with Resilience to advance manufacture of complex medicines – Harvard Gazette
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S.
Research Roundup: T-Cell Immune Response to COVID-19 Vaccines and More – BioSpace
Harvard University and National Resilience, Inc. (Resilience), a manufacturing and technology company, have established a five-year R&D alliance with a $30 million commitment from Resilience directed toward the development of complex medicines, including biologics, vaccines, nucleic acids, and cell and gene therapies. Under the alliance agreement coordinated by Harvards Office of Technology Development (OTD), Resilience will fund faculty-initiated research focused on certain novel therapeutic and biomanufacturing technologies pioneered in University labs.
The Junk Overlooked DNA Might Solve The Mystery Of Unique Human Brain – BioTecNika
Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.
BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization -…
What Makes Human Brain Unique? Around 98% of the DNA sequences in the Homo sapiens genome are non-coding regions that were previously dismissed as junk DNA. Actually, junk DNA contains a number of regulatory regions that particularly regulate gene expression
FDA Approves Genentech’s Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer – BioSpace
- Results demonstrate significant cost benefits of using Motixafortide in combination with G-CSF as standard-of-care mobilization therapy for all multiple myeloma patients undergoing autologous stem cell transplantation - - Results from pre-planned study, on top of highly significant and clinically meaningful results from Phase 3 GENESIS trial announced in May 2021, strongly support potential use of Motixafortide as standard of care in stem cell mobilization - TEL AVIV, Israel, Oct. 13, 2021 /PRNewswire/ -- BioLineRx Ltd
Nic Chapman: my MS battle and the treatment that’s given me hope – The Times
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S.
On August 16, this year Nic Chapman celebrated her birthday. My actual birthday is in September, but this was the day I was reborn, she explains.